The Michael J. Fox Foundation Parkinson's Podcast
Summary: Subscribe for coverage and analysis of current neurology/brain research, patient and caregiver profiles, drug development strategy, pioneering nonprofit management and other topics of interest in a wide-ranging series of conversations hosted by journalist and Parkinson’s patient Dave Iverson.
- Visit Website
- RSS
- Artist: Michael J. Fox Foundation
- Copyright: Copyright 2013
Podcasts:
The evolution of our understanding of genetics' role in Parkinson's disease (PD) and how that understanding will translate into drug discovery is the topic of a new podcast and upcoming Webinar.
Fox Trial Finder volunteer Gwen Schroeder recounts her first clinical trial experience to MJFF contributing editor Dave Iverson.
Fox Trial Finder volunteer Gwen Schroeder recounts her first clinical trial experience to MJFF contributing editor Dave Iverson.
Dave Iverson speaks with the CEO of Civitas, Glenn Batchelder, and MJFF staffer Maurizio Facheris, MD, MSc to learn more about how the drug works, as well as next steps.
Dave Iverson reports on recent disappointing clinical trial results of Ceregene's trophic factor therapy CERE-120.
Studies have long suggested that smokers may be less likely to get Parkinson's. Here, Dave Iverson speaks with a researcher investigating the potential of nicotine patches as a PD treatment.
Emerging evidence over the past 15 years has led researchers to believe that genetics plays a far greater role in Parkinson's disease (PD) than was once thought.
Patients have always been at the heart of what we do at The Michael J. Fox Foundation. Our dedication to improving patients' quality of life has shaped our research priorities.
Patients have always been at the heart of what we do at The Michael J. Fox Foundation. Our dedication to improving patients' quality of life has shaped our research priorities.
While levodopa is the gold standard therapy for Parkinson's disease (PD), current delivery methods have their limitations.
While levodopa is the gold standard therapy for Parkinson's disease (PD), current delivery methods have their limitations.
Understanding the genetics of Parkinson's disease could be a game changer in developing new treatments for the disease. Especially when it comes to two genetic targets: LRRK2 and alpha-synuclein.
Understanding the genetics of Parkinson's disease could be a game changer in developing new treatments for the disease. Especially when it comes to two genetic targets: LRRK2 and alpha-synuclein.
Dyskinesia refers to the excessive and uncontrollable movements that are a side effect of long-term dopamine replacement therapy in patients with Parkinson's disease (PD).
Dyskinesia refers to the excessive and uncontrollable movements that are a side effect of long-term dopamine replacement therapy in patients with Parkinson's disease (PD).
